Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Massive MGUS screening aims to unlock early myeloma clues

NCT ID NCT06472830

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated Jun 19, 2026 · Updated 30 times

Summary

This study screens 1000 adults aged 40 and older for MGUS, a condition with an abnormal blood protein that can sometimes lead to multiple myeloma. Researchers want to learn about genetic and immune factors behind MGUS, especially in diverse populations. The goal is to improve early detection and future care for everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

Conditions

The condition(s) this trial relates to.

monoclonal gammopathy of uncertain significance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.